Obermatt
See Similar Stocks →

Nippon Shinyaku

TYO:4516 · JP3717600005
PharmaceuticalsLarge

360

87
EV / EBIT93
Price / Owner Earnings55
Owner Earnings Yield96
Dividend Yield87
Price/Sales52
EV / Gross Profit100
Price/Book75
Return on Capital81
Cash Return on Capital77
Return on Equity67
EBIT Margin75
Gross Profitability64
Cash Conversion27
Accruals45
Owner Earnings Margin82
Sales growth67
Profit Growth39
Long-Term EPS Growth7
Owner Earnings Growth59
Reinvestment91
Price momentum81
Debt load89
Refinancing51
Debt Payback100
Liquidity94
Analyst ratings10
Opinion Changes36
Price Target Upside36
Market mood100
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Nippon Shinyaku clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryJapan
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeTSE
Founded1919
Employees14
Websitenippon-shinyaku.co.jp
ISINJP3717600005
Last UpdateApr 2, 2026
Index & Theme
HematologyOphthalmologyUrologyNutraceuticalHealth CareManufacturingPharmaceutical

Description

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs. The company engages in the pharmaceutical and functional food sectors, focusing on the production and sale of a wide range of products. The company’s primary business r…

Analysis

Bargain bin

Nippon Shinyaku Co., Ltd. falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.

The price is attractive. You pay 7.4× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -7% yearly growth; analysts expect -16%. The gap between price and consensus is worth watching: demanding expectations.

The trajectory is moderate and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Jun 2026

All-time low

66

Jan 2024

Average rank

91

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
52
61
47
33
Price/Earnings
91
100
93
53
Price/Book
75
76
58
45
Dividend Yield
87
79
82
47
Value (overall)
94
92
76
39

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Nippon Shinyaku with its peers
Il Dong Pharmaceutical
KSC:249420
53
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Medical Developments International
ASX:MVP
79
CountryAustralia
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
JW
KSC:096760
97
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Handok
KSC:002390
15
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
J. B. Chemicals & Pharmaceuticals
NSI:JBCHEPHARM
69
CountrySingapore
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Belite Bio
NAQ:BLTE
49
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →